

In re Application of:

Brian Bennett

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 5

PATENT

Attorney Docket No.: KILBURN1180

Renumbered per rule 126 . CC

B. In the Claims

Please cancel claims 5 to 6 without prejudice. Please amend claim 1 and claims 7 to 22 as follows.

Upon entry of the present amendment, the claims will stand as follows in the present application:

1. (currently amended) A barrier formulation which comprises an emulsion having at least an oil phase comprising a silicone compound and an aqueous phase, the viscosity of the formulation being ~~20000 cps~~ 20 Pascal second (20000 cps) or less, and the formulation further comprising an active ingredient selected from triclosan and alexidine present in an amount from 0.5 to 10% by weight of the formulation, and one or more of an emollient, an excipient, a thickener, an emulsifier, a neutralizing agent, a preservative, and water.
2. (original) A formulation as defined in claim 1 wherein the silicone compound is a silicone fluid.
3. (original) A formulation as defined in claim 2, wherein the silicone fluid is selected from dimethicone, a silicone emulsion, a dimethicone cross polymer, and a polydimethylsiloxane.
4. (currently amended) A formulation as defined in ~~any one of the preceding claims~~ claim 1, which comprises from 0.1 to 10% by weight, from 0.5 to 5% by weight, or from 1% to 2% by weight of the silicone compound.

In re Application of:
Brian Bennett
Application No.: Not Yet Assigned
US Submission Date: December 12, 2005
Based on Intl Appl: PCT/GB2004/002854
IA Filing Date: July 1, 2004
Page 6

PATENT
Attorney Docket No.: KILBURN1180

Claims 5-6 (canceled).

7 ~~75.~~ (currently amended) A formulation as defined in ~~any one of the preceding claims~~ claim 1, wherein the active ingredient is present in an amount from 0.5 to 10% by weight of the formulation, from 1 to 5% by weight, or about 2% by weight.

8 ~~86.~~ (currently amended) A formulation as defined in ~~any one of the preceding claims~~ claim 1 which further comprises a fragrance.

9 ~~97.~~ (currently amended) A formulation as defined in ~~any one of the preceding claims~~ claim 1, wherein the formulation comprises the following ingredients in the ~~approximate~~ ranges indicated:

Ingredient	Range (wt%)
Castor oil	0.5-3.0
Stearic acid	0.5-8.0
Glycerol stearate	0.1-3.0
Cetyl palmitate	0.1-2.0
Silicone fluid	0.1-10
Nipastat	0.1-0.5
Jojoba oil	0.1-0.5
Liquid paraffin	0.1-0.5
Active ingredient	0.5-10
Water	35-95
Carbomer	0.5-8.0
Aleo vera	0.1-2.0
Monopropylene glycol	2.0-15
Triethanolamine	0.1-2.0

In re Application of:

Brian Bennett

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 7

PATENT

Attorney Docket No.: KILBURN1180

10

~~108.~~ (currently amended) A barrier formulation as defined in ~~any one of the preceding claims~~ claim 1, for use as a skin barrier for humans or animals.

11

~~119.~~ (currently amended) A barrier formulation as defined in ~~any one of claims 1 to 9~~ claim 1, for use in medicine, including veterinary medicine.

12

~~1210.~~ (currently amended) Use of a formulation as defined in ~~any one of claims 1 to 9~~ claim 1, in the manufacture of a medicament for use in the treatment and/or prophylaxis of infections.

13

~~1311.~~ (currently amended) Use of a formulation as defined in ~~claim 12~~ claim 10 wherein the medicament is for use in the treatment and/or prophylaxis of skin infections.

14

~~1412.~~ (currently amended) Use of a formulation as defined in ~~claim 12~~ claim 10, wherein the medicament is for use in the treatment and/or prophylaxis of hospital acquired infections.

15

~~1513.~~ (currently amended) Use of a formulation as defined in ~~claims 12 or 13~~ claim 10, wherein the medicament is for use in the treatment and/or prophylaxis of skin infections in animals.

16

~~1614.~~ (currently amended) Use of a formulation as defined in ~~claim 15~~ claim 13, wherein the medicament is for use in the treatment and/or prophylaxis of mastitis infection and/or the spread of mastitis infection between farm animals.

In re Application of:

Brian Bennett

PATENT
Attorney Docket No.: KILBURN1180

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 8

17

~~1715~~. (currently amended) Use of a formulation as defined in ~~claim 15~~claim 13, wherein the medicament is for use in the treatment and/or prophylaxis of teat sores in animals.

18

~~1816~~. (currently amended) A method for the treatment and/or prophylaxis of skin conditions, the method comprising applying a barrier formulation as defined in ~~any one of claims 1 to 9~~claim 1 to the skin.

19

~~1917~~. (currently amended) A method for the treatment and/or prophylaxis of infection, the method comprising applying a barrier formulation of ~~any one of claims 1 to 9~~claim 1 to a human or animal.

20

~~2018~~. (currently amended) A method for the treatment and/or prevention of hospital acquired infections, the method comprising administering a barrier formulation as defined in ~~any of claims 1 to 9~~claim 1 to a health care worker.

21

~~2119~~. (currently amended) A method of manufacturing a formulation comprising an emulsion having at least an oil phase and an aqueous phase wherein the oil phase comprises a silicone compound which method comprises the steps of:

- (a) preparing an oil phase containing a silicone compound;
- (b) preparing an aqueous phase;
- (c) mixing the oil phase and the aqueous phase together;
- (d) neutralizing the mixture with a neutralizing agent.

22

~~2220~~. (currently amended) A method as defined in ~~claim 21~~claim 19 wherein the water phase is added to the oil phase to obtain an oil-in-water emulsion.